P
Protara Therapeutics, Inc. (TARA)
NGM – Real Time Price. Currency in USD
4.12
+0.12 (3.00%)
At close: Jun 26, 2026, 4:00 PM EDT
4.20
+0.08 (1.94%)
After-hours: Jun 26, 2026, 7:31 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
4.12
+0.12 (3.00%)
At close: Jun 26, 2026, 4:00 PM EDT
4.20
+0.08 (1.94%)
After-hours: Jun 26, 2026, 7:31 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $14.7M significantly exceed its total debt $3.1M, ensuring strong financial flexibility
Total current assets $140.0M exceed Total current liabilities $8.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$21.3M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 15.69 | 6.05 | 10 | |
| Quick ratio | 15.69 | 5.63 | 10 | |
| Debt to Equity | 0.02 | 0.30 | 9.0 | |
| Debt to Assets | 0.02 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -247K | -341K | -332K | -362K | -369K |
| Operating Income | -38M | -44M | -49M | -65M | -70M |
| Net Income | -66M | -40M | -45M | -57M | -63M |
| EBITDA | -37M | -43M | -49M | -64M | -70M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 6.94 | 3.0 |
| Next quarter | N/A | -11.06 | 1.0 |
| Current year | N/A | 1.6 | 2.0 |
| Next year | N/A | -19.5 | 1.0 |
| Weighted average score | 1.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -2.73 | 16.22 | -25.73 | 5.3 |
| Y/Y | 999 | -49.24 | -6.89 | -44.62 | 3.3 |
| 3y average | 999 | -0.12 | 38.85 | -31.41 | 5.5 |
| 5y average | 999 | -15.8 | 17.56 | -22.88 | 5.3 |
| Weighted average score | 4.9 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |